Skip to main content
Erschienen in: Journal of Neurology 4/2015

01.04.2015 | Original Communication

Long-term outcome of 424 childhood-onset myasthenia gravis patients

verfasst von: Mengcui Gui, Xuan Luo, Jing Lin, Yue Li, Min Zhang, Xiaofan Zhang, Mingshan Yang, Wei Wang, Bitao Bu

Erschienen in: Journal of Neurology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to describe the clinical characteristics, outcome and factors that may affect the outcome of childhood-onset myasthenia gravis (CMG) patients in China. We have followed up 424 patients with CMG for at least 5 years at Tongji Hospital. At the end of follow-up, the outcome of all the patients was measured according to MGFA Post-intervention Status. In this study, the patients have been followed up for 9.8 ± 5.4 years. The mean onset age was 5.4 ± 3.6 years. Ocular myasthenia gravis (OMG) was the major type of CMG within 2 years after onset (95 %). Thymic hyperplasia was found in 116 patients, and thymoma was confirmed in 6 patients. Acetylcholine receptor antibodies were elevated in 69.5 % of the patients. All the patients were routinely treated. Thymectomy was performed in 34 patients (8.0 %). At the end of follow-up, seventy-one patients (16.7 %) were significantly improved, 66 patients (15.6 %) remained unchanged, 53 patients (12.5 %) were worsened, and 234 patients (55.2 %) were exacerbated. Importantly, fifty OMG patients (12.4 %) had transformed into generalized myasthenia gravis (GMG) over 2 years after onset. Thymectomy did not effectively reduce the transformation from OMG to GMG. However, GMG cases significantly benefited from the surgery. This study indicated that the cases with autoimmune CMG account for over 50 % in Chinese MG population. The long-term follow-up discloses that CMG patients have a low percentage of improvement, and a high percentage of worsening and exacerbation. The treatment should not be withdrawn too early after the patients obtain complete stable remission. More studies are needed to gain better control of CMG symptoms.
Literatur
1.
Zurück zum Zitat Phillips LN, Torner JC, Anderson MS, Cox GM (1992) The epidemiology of myasthenia gravis in central and western Virginia. Neurology 42:1888–1893CrossRefPubMed Phillips LN, Torner JC, Anderson MS, Cox GM (1992) The epidemiology of myasthenia gravis in central and western Virginia. Neurology 42:1888–1893CrossRefPubMed
2.
Zurück zum Zitat Huang X, Liu WB, Men LN, Feng HY, Li Y, Luo CM, Qiu L (2013) Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci 34:911–917CrossRefPubMed Huang X, Liu WB, Men LN, Feng HY, Li Y, Luo CM, Qiu L (2013) Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci 34:911–917CrossRefPubMed
3.
Zurück zum Zitat Zhang X, Yang M, Xu J, Zhang M, Lang B, Wang W, Vincent A (2007) Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry 78:386–390PubMedCentralCrossRefPubMed Zhang X, Yang M, Xu J, Zhang M, Lang B, Wang W, Vincent A (2007) Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry 78:386–390PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Wang W, Chen YP, Wang ZK, Wei DN, Yin L (2013) A cohort study on myasthenia gravis patients in China. Neurol Sci 34:1759–1764CrossRefPubMed Wang W, Chen YP, Wang ZK, Wei DN, Yin L (2013) A cohort study on myasthenia gravis patients in China. Neurol Sci 34:1759–1764CrossRefPubMed
5.
Zurück zum Zitat Ashraf VV, Taly AB, Veerendrakumar M, Rao S (2006) Myasthenia gravis in children: a longitudinal study. Acta Neurol Scand 114:119–123CrossRefPubMed Ashraf VV, Taly AB, Veerendrakumar M, Rao S (2006) Myasthenia gravis in children: a longitudinal study. Acta Neurol Scand 114:119–123CrossRefPubMed
6.
Zurück zum Zitat Bever CJ, Aquino AV, Penn AS, Lovelace RE, Rowland LP (1983) Prognosis of ocular myasthenia. Ann Neurol 14:516–519CrossRefPubMed Bever CJ, Aquino AV, Penn AS, Lovelace RE, Rowland LP (1983) Prognosis of ocular myasthenia. Ann Neurol 14:516–519CrossRefPubMed
7.
Zurück zum Zitat Kupersmith MJ, Latkany R, Homel P (2003) Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 60:243–248CrossRefPubMed Kupersmith MJ, Latkany R, Homel P (2003) Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 60:243–248CrossRefPubMed
9.
Zurück zum Zitat Huze C, Bauche S, Richard P et al (2009) Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 85:155–167PubMedCentralCrossRefPubMed Huze C, Bauche S, Richard P et al (2009) Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 85:155–167PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Maselli RA, Ng JJ, Anderson JA et al (2009) Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. J Med Genet 46:203–208PubMedCentralCrossRefPubMed Maselli RA, Ng JJ, Anderson JA et al (2009) Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. J Med Genet 46:203–208PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Busch C, Machens A, Pichlmeier U, Emskotter T, Izbicki JR (1996) Long-term outcome and quality of life after thymectomy for myasthenia gravis. Ann Surg 224:225–232PubMedCentralCrossRefPubMed Busch C, Machens A, Pichlmeier U, Emskotter T, Izbicki JR (1996) Long-term outcome and quality of life after thymectomy for myasthenia gravis. Ann Surg 224:225–232PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Jaretzki AR, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23CrossRefPubMed Jaretzki AR, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23CrossRefPubMed
15.
16.
Zurück zum Zitat Melbourne CR, Forrester S, Gray R, Tapper J, Trotman H (2012) Myasthenia gravis in Jamaican children: a 12-year institutional review. Paediatr Int Child Health 32:47–50CrossRef Melbourne CR, Forrester S, Gray R, Tapper J, Trotman H (2012) Myasthenia gravis in Jamaican children: a 12-year institutional review. Paediatr Int Child Health 32:47–50CrossRef
17.
Zurück zum Zitat Bu B, Yang M, Xu J, Gong F, Jiang X, Nie X (1999) The clinical study and HLA genotyping of 112 familial myasthenia gravis patients. J Tongji Med Univ 19:46–49CrossRefPubMed Bu B, Yang M, Xu J, Gong F, Jiang X, Nie X (1999) The clinical study and HLA genotyping of 112 familial myasthenia gravis patients. J Tongji Med Univ 19:46–49CrossRefPubMed
18.
Zurück zum Zitat Fekih-Mrissa N, Klai S, Zaouali J, Gritli N, Mrissa R (2013) Association of HLA-DR/DQ polymorphism with myasthenia gravis in Tunisian patients. Clin Neurol Neurosurg 115:32–36CrossRefPubMed Fekih-Mrissa N, Klai S, Zaouali J, Gritli N, Mrissa R (2013) Association of HLA-DR/DQ polymorphism with myasthenia gravis in Tunisian patients. Clin Neurol Neurosurg 115:32–36CrossRefPubMed
19.
Zurück zum Zitat Matsuki K, Juji T, Tokunaga K, Takamizawa M, Maeda H, Soda M, Nomura Y, Segawa M (1990) HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest 86:392–399PubMedCentralCrossRefPubMed Matsuki K, Juji T, Tokunaga K, Takamizawa M, Maeda H, Soda M, Nomura Y, Segawa M (1990) HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest 86:392–399PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Luchanok U, Kaminski HJ (2008) Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 21:8–15CrossRefPubMed Luchanok U, Kaminski HJ (2008) Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 21:8–15CrossRefPubMed
21.
Zurück zum Zitat Kalb B, Matell G, Pirskanen R, Lambe M (2002) Epidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden. Neuroepidemiology 21:221–225CrossRefPubMed Kalb B, Matell G, Pirskanen R, Lambe M (2002) Epidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden. Neuroepidemiology 21:221–225CrossRefPubMed
22.
Zurück zum Zitat Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, Raissy HH, Van Natta ML, Tonascia J, Strunk RC (2012) Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 367:904–912PubMedCentralCrossRefPubMed Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, Raissy HH, Van Natta ML, Tonascia J, Strunk RC (2012) Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 367:904–912PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Wang SJ, Yang YH, Lin YT, Yang CM, Chiang BL (2002) Attained adult height in juvenile rheumatoid arthritis with or without corticosteroid treatment. Clin Rheumatol 21:363–368CrossRefPubMed Wang SJ, Yang YH, Lin YT, Yang CM, Chiang BL (2002) Attained adult height in juvenile rheumatoid arthritis with or without corticosteroid treatment. Clin Rheumatol 21:363–368CrossRefPubMed
24.
Zurück zum Zitat Ionita CM, Acsadi G (2013) Management of juvenile myasthenia gravis. Pediatr Neurol 48:95–104CrossRefPubMed Ionita CM, Acsadi G (2013) Management of juvenile myasthenia gravis. Pediatr Neurol 48:95–104CrossRefPubMed
25.
Zurück zum Zitat Raica M, Cimpean AM, Ribatti D (2008) Myasthenia gravis and the thymus gland. A historical review. Clin Exp Med 8:61–64CrossRefPubMed Raica M, Cimpean AM, Ribatti D (2008) Myasthenia gravis and the thymus gland. A historical review. Clin Exp Med 8:61–64CrossRefPubMed
26.
Zurück zum Zitat Spillane J, Hayward M, Hirsch NP, Taylor C, Kullmann DM, Howard RS (2013) Thymectomy: role in the treatment of myasthenia gravis. J Neurol 260:1798–1801CrossRefPubMed Spillane J, Hayward M, Hirsch NP, Taylor C, Kullmann DM, Howard RS (2013) Thymectomy: role in the treatment of myasthenia gravis. J Neurol 260:1798–1801CrossRefPubMed
27.
28.
Zurück zum Zitat Mineo TC, Ambrogi V (2013) Outcomes after thymectomy in class I myasthenia gravis. J Thorac Cardiovasc Surg 145:1319–1324CrossRefPubMed Mineo TC, Ambrogi V (2013) Outcomes after thymectomy in class I myasthenia gravis. J Thorac Cardiovasc Surg 145:1319–1324CrossRefPubMed
29.
Zurück zum Zitat Liu N, Liu Q, Wu X, Liu K, Vadis Q (2014) Predictors of outcome of myasthenic crisis. Neurol Sci 35:1109–1114CrossRef Liu N, Liu Q, Wu X, Liu K, Vadis Q (2014) Predictors of outcome of myasthenic crisis. Neurol Sci 35:1109–1114CrossRef
30.
Zurück zum Zitat Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347:911–920CrossRefPubMed Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347:911–920CrossRefPubMed
31.
Zurück zum Zitat Correale J, Fiol M, Gilmore W (2006) The risk of relapses in multiple sclerosis during systemic infections. Neurology 67:652–659CrossRefPubMed Correale J, Fiol M, Gilmore W (2006) The risk of relapses in multiple sclerosis during systemic infections. Neurology 67:652–659CrossRefPubMed
32.
Zurück zum Zitat Andersen O, Lygner PE, Bergstrom T, Andersson M, Vahlne A (1993) Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 240:417–422CrossRefPubMed Andersen O, Lygner PE, Bergstrom T, Andersson M, Vahlne A (1993) Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 240:417–422CrossRefPubMed
33.
Zurück zum Zitat Esposito S, Bosis S, Semino M, Rigante D (2014) Infections and systemic lupus erythematosus. Eur J Clin Microbiol Infect Dis 33:1467–1475CrossRefPubMed Esposito S, Bosis S, Semino M, Rigante D (2014) Infections and systemic lupus erythematosus. Eur J Clin Microbiol Infect Dis 33:1467–1475CrossRefPubMed
34.
Zurück zum Zitat Panda S, Goyal V, Behari M, Singh S, Srivastava T (2004) Myasthenic crisis: a retrospective study. Neurol India 52:453–456PubMed Panda S, Goyal V, Behari M, Singh S, Srivastava T (2004) Myasthenic crisis: a retrospective study. Neurol India 52:453–456PubMed
35.
Zurück zum Zitat Pineles SL, Avery RA, Moss HE, Finkel R, Blinman T, Kaiser L, Liu GT (2010) Visual and systemic outcomes in pediatric ocular myasthenia gravis. Am J Ophthalmol 150:453–459CrossRefPubMed Pineles SL, Avery RA, Moss HE, Finkel R, Blinman T, Kaiser L, Liu GT (2010) Visual and systemic outcomes in pediatric ocular myasthenia gravis. Am J Ophthalmol 150:453–459CrossRefPubMed
36.
Zurück zum Zitat Wong V, Hawkins BR, Yu YL (1992) Myasthenia gravis in Hong Kong Chinese. 2 Paediatric disease. Acta Neurol Scand 86:68–72CrossRefPubMed Wong V, Hawkins BR, Yu YL (1992) Myasthenia gravis in Hong Kong Chinese. 2 Paediatric disease. Acta Neurol Scand 86:68–72CrossRefPubMed
Metadaten
Titel
Long-term outcome of 424 childhood-onset myasthenia gravis patients
verfasst von
Mengcui Gui
Xuan Luo
Jing Lin
Yue Li
Min Zhang
Xiaofan Zhang
Mingshan Yang
Wei Wang
Bitao Bu
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 4/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7638-2

Weitere Artikel der Ausgabe 4/2015

Journal of Neurology 4/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

03.05.2024 Parkinson-Krankheit Nachrichten

Kann eine frühzeitige Stuhltransplantation das Fortschreiten von Parkinson-Symptomen verlangsamen? Die Ergebnisse einer randomisierten Phase-2-Studie scheinen dafür zu sprechen.

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

02.05.2024 Hirnblutung Nachrichten

Erhalten Personen mit einer spontanen Hirnblutung innerhalb von zwei Stunden nach Symptombeginn eine Tranexamsäure-Therapie, kann dies weder die Hämatomexpansion eindämmen noch die Mortalität senken.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.